PGI24 Cost-Effectiveness Analysis of 48-Week Peginterferon Alpha-2a Under RGT Strategy Versus 3 Years Entecavir for the Treatment of HBeAg-Positive Chronic Hepatitis B in China
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.773
https://www.valueinhealthjournal.com/article/S1098-3015(12)02486-2/fulltext
Title :
PGI24 Cost-Effectiveness Analysis of 48-Week Peginterferon Alpha-2a Under RGT Strategy Versus 3 Years Entecavir for the Treatment of HBeAg-Positive Chronic Hepatitis B in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02486-2&doi=10.1016/j.jval.2012.08.773
First page :
A330
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
284